Shire Launches Cuvitru in U.S. for Primary Immunodeficiency

Shire plc SHPG announced the launch of Cuvitru in the U S Cuvitru an immune globulin subcutaneous 20 solution gained FDA approval for primary humoral immunodeficiency in adult and pediatric patients aged two years and older in Sep 2016 According to the press release issued by